This activity is supported by an educational grant from Indivior.
Daniel Abazia, PharmD, BCPS
Clinical Assistant Professor
Department of Pharmacy Practice and Administration
Ernest Mario School of Pharmacy
Rutgers, The State University of New Jersey
Piscataway, New Jersey
Melissa B. Weimer, DO, MCR, FASAM
Chief of Division of Behavioral Health & Addiction Medicine
St. Peter's Health Partners
SPHP Addiction Recovery Center (SPARC)
Albany, New York
Opioid dependence (OD) has reached epidemic proportions in the United States, and physicians, pharmacists, and nurse practitioners have a critical role in improving outcomes in patients being treated for OD. This activity will focus on current and emerging treatment options for OD; explore long-acting injectables for OD, including their clinical benefits; and discuss the importance of a multidisciplinary approach for treating OD.
At the completion of this activity, the participant will be able to:
Explain current treatment options to address the growing incidence of opioid dependence.
Explore the mechanism of actions, monitoring parameters, and clinical benefits of long-acting injectables for opioid dependence.
Identify best practices that support a multidisciplinary approach to care for treating opioid dependence.
May 31, 2018
May 31, 2019
Pharmacists, Physicians, Nurse Practitioners
Type of Activity:
This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of Physicians’ Education Resource®
, LLC and Pharmacy Times
Continuing Education™. Physicians’ Education Resource®
, LLC is accredited by the ACCME to provide continuing medical education for physicians.
Physicians’ Education Resource®
, LLC designates this live activity for a maximum of 1.5 AMA PRA Category 1 Credits
™. Physicians should claim only the credit commensurate with the extent of their participation in the activity
To receive CPE credit, participants must complete the pretest, listen to the recorded podcast in its entirety, complete the posttest, and complete the online activity evaluation. After successful completion of the online posttest and activity evaluation, you can submit your credit. You may view your credit within 48 hours at www.mycpemonitor.net. All participants must request credit before May 31, 2019. CE credit will not be issued after this date.
Important: If you attended the live symposium held on April 14, 2018, in San Diego, California, you will not be eligible to receive credit for this on-demand activity.
Melissa B. Weimer, DO, MCR, FASAM, has the following relevant financial relationships with commercial interests to disclose:
- Honorarium: from Indivior for a one-time speaking event, medication Indivior markets was not mentioned.
Daniel T. Abazia, PharmD, BCPS, CPE, has the following relevant financial relationship with a commercial interest to disclose:
- Consultant: Pacira Pharmaceuticals, Inc.
Pharmacy Times Continuing Education™
- David Heckard; Maryjo Dixon, RPh; Jyoti Arya, PharmD, RPh; Nicole Grassano; and Susan Pordon have no relevant financial relationships with commercial interests to disclose.
An anonymous peer reviewer is used as part of content validation and conflict resolution. The peer reviewer has no relevant financial relationships with commercial interests to disclose.
Disclosure Policy and Resolution of Conflicts of Interest (COI)
As a sponsor accredited by the ACCME, it is the policy of Physicians’ Education Resource®
, LLC (PER®
) to ensure fair balance, independence, objectivity, and scientific rigor in all of its CME activities. In compliance with ACCME guidelines, PER®
requires everyone who is in a position to control the content of a CME activity to disclose all relevant financial relationships with commercial interests. The ACCME defines “relevant financial relationships” as financial relationships in any amount occurring within the past 12 months that creates a COI.
is required by ACCME to resolve all COI. PER®
has identified and resolved all COI prior to the start of this activity by using a multistep process.
Continuing professional education (CPE) activities are offered solely for educational purposes and do not constitute any form of professional advice or referral. Discussions concerning drugs, dosages, and procedures may reflect the clinical experience of the author(s) or they may be derived from the professional literature or other sources and may suggest uses that are investigational in nature and not approved labeling or indications. Participants are encouraged to refer to primary references or full prescribing information resources.
This CME activity may or may not discuss investigational, unapproved, or off-label use of drugs. Participants are advised to consult prescribing information for any products discussed. The information provided in this CME activity is for continuing medical and nursing education purposes only and is not meant to substitute for the independent clinical judgment of a physician relative to diagnostic, treatment, or management options for a specific patient’s medical condition. The opinions expressed in the content are solely those of the individual faculty members and do not reflect those of PER®